The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Cancer cachexia: Developing multimodal therapy for a multidimensional problem
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., Wackerhage, H., Taylor, P. M., & Rennie, M. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2640fje · Cited by 1,211 · cited 2×
“Furthermore, sarcopaenia is exacerbated by chronic illness, inadequate diet and inactivity.(26) However, one of the predominant mechanisms appears to be the anabolic resistance of elderly muscles to post-prandial amino acid loading.”
BackgroundSymptom Prevalence in Patients with Incurable Cancer: A Systematic Review
Teunissen, S. C. C. M., Wesker, W., Kruitwagen, C., de Haes, H. C. J. M., Voest, E. E., & de Graeff, A. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.015 · Cited by 990
Tumor Necrosis Factor, Other Cytokines and Disease
Tracey, K. J., & Cerami, A. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.001533 · Cited by 783
Fearon, K. C., Voss, A. C., & Hustead, D. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1345 · Cited by 779
Self-citationLecker, S. H., Solomon, V., Mitch, W. E., & Goldberg, A. L. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.1.227s · Cited by 732
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Mourtzakis, M., Mulder, K. E., Reiman, T., Butts, C. A., Scarfe, A. G., & Sawyer, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3067 · Cited by 619
Fearon, K. C. H. (2003) · Gut · doi:10.1136/gut.52.10.1479 · Cited by 603
Self-citation
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Self-citationBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Self-citationCancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
Self-citationReversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
The Multidisciplinary Team (MDT) Approach and Quality of Care
Taberna, M., Gil Moncayo, F., Jané-Salas, E., Antonio, M., Arribas, L., Vilajosana, E., Peralvez Torres, E., & Mesía, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00085 · Cited by 513
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia
Peixoto da Silva, S., Santos, J. M. O., Costa e Silva, M. P., Gil da Costa, R. M., & Medeiros, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12528 · Cited by 371
Physical Exercise for Cancer Patients with Advanced Disease: A Randomized Controlled Trial
Oldervoll, L. M., Loge, J. H., Lydersen, S., Paltiel, H., Asp, M. B., Nygaard, U. V., Oredalen, E., Frantzen, T. L., Lesteberg, I., Amundsen, L., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0133 · Cited by 286
Levolger, S., van Vugt, J. L. A., de Bruin, R. W. F., & IJzermans, J. N. M. (2015) · British Journal of Surgery · doi:10.1002/bjs.9893 · Cited by 270
Cancer cachexia—pathophysiology and management
Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., & Inui, A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0787-0 · Cited by 268
Challenges to evaluating complex interventions: a content analysis of published papers
Datta, J., & Petticrew, M. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-568 · Cited by 265
Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer
Nipp, R. D., Fuchs, G., El-Jawahri, A., Mario, J., Troschel, F. M., Greer, J. A., Gallagher, E. R., Jackson, V. A., Kambadakone, A., Hong, T. S., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0255 · Cited by 265
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
Skeletal Muscle Wasting and Renewal: A Pivotal Role of Myokine IL-6
Belizário, J. E., Fontes-Oliveira, C. C., Borges, J. P., Kashiabara, J. A., & Vannier, E. (2016) · SpringerPlus · doi:10.1186/s40064-016-2197-2 · Cited by 244
van Vugt, J. L. A., Levolger, S., Gharbharan, A., Koek, M., Niessen, W. J., Burger, J. W. A., Willemsen, S. P., de Bruin, R. W. F., & IJzermans, J. N. M. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12158 · Cited by 217
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
Wang, G., Biswas, A. K., Ma, W., Kandpal, M., Coker, C., Grandgenett, P. M., Hollingsworth, M. A., Jain, R., Tanji, K., Lόpez-Pintado, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0054-2 · Cited by 188
Sjøblom, B., Grønberg, B. H., Wentzel-Larsen, T., Baracos, V. E., Hjermstad, M. J., Aass, N., Bremnes, R. M., Fløtten, Ø., Bye, A., & Jordhøy, M. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.010 · Cited by 143
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Antibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice
Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., & Lynch, G. S. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00121.2011 · Cited by 111
Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
Segatto, M., Fittipaldi, R., Pin, F., Sartori, R., Dae Ko, K., Zare, H., Fenizia, C., Zanchettin, G., Pierobon, E. S., Hatakeyama, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01645-7 · Cited by 101
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.
Navari, R. M., & Brenner, M. C. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0739-7 · Cited by 99
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
Metadata
- Authors
- Fearon, K. C. H.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 44
- Issue
- 8
- Pages
- 1124-1132
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2118598881
- Cited by
- 444
- References
- 66
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
